"After that, they hopefully make a public bid for all listed shares of RVX...plus a private bid for Zenith.  They can haggle about the eventual price...but the check will be for both companies...not just one."

They might even need three checks. One for Resverlogix, one for Zenith Epigenetics Ltd (ZEL), and one for Zenith Capital Corp (ZCC; who holds the Royalty preferred shares (RPS)).

The re-structuring of Zenith would allow ZEL or ZCC to be sold separately from one another. If a company buys Resverlogix, then they may want ZCC in order to have those RPS. And if they want the ZEL clinical programs, compounds and other intellectual property, they could cut that third check for ZEL.

A successful BETonMACE would immediately increase the value of ZCC. A successful BETonMACE could also indirectly inrease the confidence in and value of ZEL. And of course, good news out of ZEL would immediately increase the value of ZEL. The ZEL prostate cancer trial is wrapping up and is listed with estimated completion date of June 2019. So we might be hearing news on ZEL and ZEN-3694 soon.

BearDownAZ